Table 1 Different batches of gliclazide loaded PLGA SGNCs formulations and their physicochemical characterizations.

From: Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model

Formulation code

PS ± SD (nm)

PDI ± SD

ZP ± SD (mV)

EE(%) ± SD

SGNCF1

106.3 ± 2.69c,f,h

0.222 ± 0.104

−18.2 ± 1.30b,c,e,f,i

86.27 ± 0.222

SGNCF2

114.7 ± 2.77c,f,h

0.216 ± 0.004

−23.1 ± 2.08a,c,d,e,f,g,h,i

84.40 ± 0.222

SGNCF3

220.2 ± 8.50a,b,d,e,g,h

0.284 ± 0.022

−8.80 ± 0.66a,b,d,e,g,h

91.50 ± 0.007

SGNCF4

120.0 ± 4.11c,f,h

0.221 ± 0.104

−17.2 ± 1.57b,c,e,f,i

84.13 ± 0.001

SGNCF5

94.89 ± 5.36c,f,h

0.217 ± 0.010

−18.4 ± 1.15b,c,e,f,i

85.87 ± 0.002

SGNCF6

176.8 ± 6.92a,b,c,d,e,g,h,i

0.218 ± 0.007

−11.6 ± 1.00a,b,d,e,g,h

79.65 ± 0.006

SGNCF7

102.5 ± 0.53c,f,h

0.228 ± 0.002

−18.3 ± 1.15b,c,e,f,i

84.10 ± 0.003

SGNCF8

110.1 ± 9.01c,f,h

0.161 ± 0.010

−18.4 ± 0.44b,c,e,f,i

87.40 ± 0.001

SGNCF9

223.4 ± 3.03a,b,d,e,f,g,h,i

0.245 ± 0.004

10.4 ± 1.04a,b,d,e,g,h

79.03 ± 0.010

  1. PS: particle size; PDI: polydispersity index; ZP: zetapotential; EE: entrapment efficiency; SD: standard deviation; (n = 3). Samples were analysed using ANOVA Dunnett’s C statistical test. aP < 0.05 vs. SGNCF1; bP < 0.05 vs. SGNCF2; cP < 0.05 vs. SGNCF3; dP < 0.05 vs. SGNCF4; eP < 0.05 vs. SGNCF5; fP < 0.05 vs. SGNCF6; gP < 0.05 vs. SGNCF7; hP < 0.05 vs. SGNCF8; iP < 0.05 vs. SGNCF9.